Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (251-260 of 404) with videos related to

Pageof 41
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
Journal of Gastroenterology and Hepatology|January 15, 2015
Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infectionMatthew T Kitson, Jacob George, Gregory J Dore, et al.
Journal of Viral Hepatitis|April 14, 2019
Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness studySahar Bajis, Jason Grebely, Lucy Cooper, et al.
Hepatology Communications|November 3, 2021
High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C StudyJasmine Yee, Joanne M Carson, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.
Journal of Viral Hepatitis|May 18, 2022
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohortJoanne M Carson, Behzad Hajarizadeh, Josh Hanson, et al.
The Journal of Infectious Diseases|March 4, 2014
Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapyMegan Crane, Anchalee Avihingsanon, Reena Rajasuriar, et al.
The International Journal on Drug Policy|April 12, 2024
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage studyHeather Valerio, Alison D Marshall, Anna Conway, et al.
Hepatology (Baltimore, Md.)|August 31, 2010
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infectionJason Grebely, Kathy Petoumenos, Margaret Hellard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2020
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisJason Grebely, Lucy Tran, Louisa Degenhardt, et al.
Pageof 41

Showing results (251-260 of 404) with videos related to

Sort By:
Pageof 41
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
Journal of Gastroenterology and Hepatology|January 15, 2015
Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infectionMatthew T Kitson, Jacob George, Gregory J Dore, et al.
Journal of Viral Hepatitis|April 14, 2019
Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness studySahar Bajis, Jason Grebely, Lucy Cooper, et al.
Hepatology Communications|November 3, 2021
High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C StudyJasmine Yee, Joanne M Carson, Behzad Hajarizadeh, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.
Journal of Viral Hepatitis|May 18, 2022
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohortJoanne M Carson, Behzad Hajarizadeh, Josh Hanson, et al.
The Journal of Infectious Diseases|March 4, 2014
Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapyMegan Crane, Anchalee Avihingsanon, Reena Rajasuriar, et al.
The International Journal on Drug Policy|April 12, 2024
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage studyHeather Valerio, Alison D Marshall, Anna Conway, et al.
Hepatology (Baltimore, Md.)|August 31, 2010
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infectionJason Grebely, Kathy Petoumenos, Margaret Hellard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2020
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysisJason Grebely, Lucy Tran, Louisa Degenhardt, et al.
Pageof 41